Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis

G.J. Strijkers, E. Kluza, G.A.F. Tilborg, van, D.W.J. Schaft, van der, A.W. Griffioen, W.J.M. Mulder, K. Nicolay

Research output: Contribution to journalArticleAcademicpeer-review

77 Citations (Scopus)
59 Downloads (Pure)

Abstract

Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.
Original languageEnglish
Pages (from-to)161-173
Number of pages13
JournalAngiogenesis
Volume13
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

Liposomes
Contrast Media
Tumors
Imaging techniques
Magnetic resonance
Magnetic Resonance Imaging
Neoplasms
Technology
Therapeutics
Vascular Endothelium
Drug delivery
Ligands
Visualization
Tissue
Growth
Molecules
Monitoring
Pharmaceutical Preparations

Cite this

@article{4f9e3092390f40f5a8c4cf0d9d669d50,
title = "Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis",
abstract = "Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.",
author = "G.J. Strijkers and E. Kluza and {Tilborg, van}, G.A.F. and {Schaft, van der}, D.W.J. and A.W. Griffioen and W.J.M. Mulder and K. Nicolay",
year = "2010",
doi = "10.1007/s10456-010-9165-1",
language = "English",
volume = "13",
pages = "161--173",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer",
number = "2",

}

Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. / Strijkers, G.J.; Kluza, E.; Tilborg, van, G.A.F.; Schaft, van der, D.W.J.; Griffioen, A.W.; Mulder, W.J.M.; Nicolay, K.

In: Angiogenesis, Vol. 13, No. 2, 2010, p. 161-173.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis

AU - Strijkers, G.J.

AU - Kluza, E.

AU - Tilborg, van, G.A.F.

AU - Schaft, van der, D.W.J.

AU - Griffioen, A.W.

AU - Mulder, W.J.M.

AU - Nicolay, K.

PY - 2010

Y1 - 2010

N2 - Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.

AB - Angiogenesis is essential for tumor growth and metastatic potential and for that reason considered an important target for tumor treatment. Noninvasive imaging technologies, capable of visualizing tumor angiogenesis and evaluating the efficacy of angiostatic therapies, are therefore becoming increasingly important. Among the various imaging modalities, magnetic resonance imaging (MRI) is characterized by a superb spatial resolution and anatomical soft-tissue contrast. Revolutionary advances in contrast agent chemistry have delivered versatile angiogenesis-specific molecular MRI contrast agents. In this paper, we review recent advances in the preclinical application of paramagnetic and fluorescent liposomes for noninvasive visualization of the molecular processes involved in tumor angiogenesis. This liposomal contrast agent platform can be prepared with a high payload of contrast generating material, thereby facilitating its detection, and is equipped with one or more types of targeting ligands for binding to specific molecules expressed at the angiogenic site. Multimodal liposomes endowed with contrast material for complementary imaging technologies, e.g., MRI and optical, can be exploited to gain important preclinical insights into the mechanisms of binding and accumulation at angiogenic vascular endothelium and to corroborate the in vivo findings. Interestingly, liposomes can be designed to contain angiostatic therapeutics, allowing for image-supervised drug delivery and subsequent monitoring of therapeutic efficacy.

U2 - 10.1007/s10456-010-9165-1

DO - 10.1007/s10456-010-9165-1

M3 - Article

VL - 13

SP - 161

EP - 173

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -